CRISPR Therapeutics AG (CRSP) Operating Leases (2019 - 2026)

CRISPR Therapeutics AG has disclosed Operating Leases across 8 years of filings, most recently posting $183.6 million for Q1 2026.

• Operating Leases for Q1 2026 came in at $183.6 million, down 9.06% year-over-year; the trailing twelve-month figure through Mar 2026 was $183.6 million (down 9.06% YoY), and the FY2025 annual result was $188.2 million, down 8.84% from the prior year.
• Operating Leases came in at $183.6 million for Q1 2026 at CRISPR Therapeutics AG, down from $188.2 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $234.2 million in Q2 2022 to a low of $183.6 million in Q1 2026.
• The 5-year median for Operating Leases is $218.9 million (2024), against an average of $214.1 million.
• Across the five-year window, Operating Leases jumped 361.27% in 2022 and declined 9.06% in 2026, its largest moves.
• CRISPR Therapeutics AG's Operating Leases stood at $228.2 million in 2022, then dropped by 2.27% to $223.0 million in 2023, then dropped by 7.44% to $206.4 million in 2024, then declined by 8.84% to $188.2 million in 2025, then slipped by 2.45% to $183.6 million in 2026.
• The last three Operating Leases figures came in at $183.6 million (Q1 2026), $188.2 million (Q4 2025), and $192.8 million (Q3 2025), per Business Quant data.